Photodynamic therapy in combination with intravitreal ziv-aflibercept and aflibercept injection in patients with chronic or repeatedly recurrent acute central serous chorioretinopathy: a single-center retrospective study

References

• WangMMunchICHaslerPWPrünteCLarsenMCentral serous chorioretinopathyActa Ophthalmol200886212614517662099
   PubMed Web of Science ®Google Scholar
• KurodaSIkunoYYasunoYChoroidal thickness in central serous chorioretinopathyRetina201333230230823064424
   PubMed Web of Science ®Google Scholar
• ChungYRKimJWKimSWLeeKChoroidal thickness in patients with central serous chorioretinopathy: assessment of Haller and Sattler LayersRetina20163691652165726934451
   PubMed Web of Science ®Google Scholar
• LiewGQuinGGilliesMFraser-BellSCentral serous chorioretinopathy: a review of epidemiology and pathophysiologyClin Exp Ophthalmol201341220121422788735
   PubMed Web of Science ®Google Scholar
• FickerLVafidisGWhileALeaverPLong-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathyBr J Ophthalmol198872118298343061449
   PubMed Web of Science ®Google Scholar
• GäckleHCLangGEFreisslerKALangGKCentral serous chorioretinopathy. Clinical, fluorescein angiography and demographic aspectsOphthalmologe1998958529533 German [with English abstract]9782727
   PubMed Web of Science ®Google Scholar
• KimYYFlaxelCJFactors influencing the visual acuity of chronic central serous chorioretinopathyKorean J Ophthalmol2011252909721461220
   PubMedGoogle Scholar
• WangMSSanderBLarsenMRetinal atrophy in idiopathic central serous chorioretinopathyAm J Ophthalmol2002133678779312036670
   PubMed Web of Science ®Google Scholar
• Bonini FilhoMAde CarloTEFerraraDAssociation of choroidal neovascularization and central serous chorioretinopathy with optical coherence tomography angiographyJAMA Ophthalmol2015133889990625996386
   PubMed Web of Science ®Google Scholar
• BreukinkMBDingemansAJden HollanderAIChronic central serous chorioretinopathy: long-term follow-up and vision-related quality of lifeClin Ophthalmol201711394628053499
   PubMed Web of Science ®Google Scholar
• SalehiMWenickASLawHAEvansJRGehlbachPInterventions for central serous chorioretinopathy: a network meta-analysisCochrane Database Syst Rev201512CD011841
   Google Scholar
• ErikitolaOCCrosby-NwaobiRLoteryAJSivaprasadSPhotodynamic therapy for central serous chorioretinopathyEye (Lond)201428894495724946843
   PubMed Web of Science ®Google Scholar
• YamanAArikanGSaatciAOCingilGChoroidal neovascularization following photodynamic therapy in a patient with chronic central serous chorioretinopathyBoll Soc Belge Ophthalmol20073036973
   Google Scholar
• LeePYKimKSLeeWKSevere choroidal ischemia following photodynamic therapy for pigment epithelial detachment and chronic central serous chorioretinopathyJpn J Ophthalmol2009531525619184311
   PubMed Web of Science ®Google Scholar
• ColuccielloMChoroidal neovascularization complicating photodynamic therapy for central serous retinopathyRetina200626223924216467692
   PubMed Web of Science ®Google Scholar
• Schmidt-ErfurthUSchlötzer-SchrehardUCursiefenCMichelsSBeckendorfANaumannGOInfluence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factorInvest Ophthalmol Vis Sci200344104473448014507895
   PubMed Web of Science ®Google Scholar
• MichelsSSchmidt-ErfurthUSequence of early vascular events after photodynamic therapyInvest Ophthalmol Vis Sci20034452147215412714655
   PubMed Web of Science ®Google Scholar
• FerraraNVascular endothelial growth factor: basic science and clinical progressEndocr Rev200425458161115294883
   PubMed Web of Science ®Google Scholar
• LaiTYChanWMLiHLaiRYLiuDTLamDSSafety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot studyBr J Ophthalmol200690786987416597666
   PubMed Web of Science ®Google Scholar
• ReibaldiMCardasciaNLongoAStandard-fluence versus low-fluence photodynamic therapy in chronic central serous chori-oretinopathy: a nonrandomized clinical trialAm J Ophthalmol20101492307.e2315.e219896635
   PubMed Web of Science ®Google Scholar
• ShinJYWooSJYuHGParkKHComparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathyRetina201131111912620890242
   PubMed Web of Science ®Google Scholar
• InoueRSawaMTsujikawaMGomiFAssociation between the efficacy of photodynamic therapy and indocyanine green angiography findings for central serous chorioretinopathyAm J Ophthalmol20101493441446.e1e220172070
   PubMed Web of Science ®Google Scholar
• TsengCCChenSNLong-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathyBr J Ophthalmol20159981070107725680621
   PubMed Web of Science ®Google Scholar
• ChungYRSeoEJLewHMLeeKHLack of positive effect of intra-vitreal bevacizumab in central serous chorioretinopathy: meta-analysis and reviewEye (Lond)201327121339134624202051
   PubMed Web of Science ®Google Scholar
• InoueMKadonosonoKWatanabeYKobayashiSYamaneSArakawaAResults of one-year follow-up examinations after intra-vitreal bevacizumab administration for chronic central serous chorioretinopathyOphthalmologica20112251374020693820
   PubMed Web of Science ®Google Scholar
• ArtunayOYuzbasiogluERasierRSengulABahceciogluHIntravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical studyCurr Eye Res2010352919820136418
   PubMed Web of Science ®Google Scholar
• EntezariMRamezaniAYaseriMIntravitreal bevacizumab for treatment of refractory central serous choroidoretinopathyKorean J Ophthalmol201226213914222511842
   PubMedGoogle Scholar
• OkamotoMMatsuuraTOgataNChoroidal thickness and choroidal blood flow after intravitreal bevacizumab injection in eyes with central serous chorioretinopathyOphthalmic Surg Lasers Imaging Retina2015461253225559505
   PubMed Web of Science ®Google Scholar
• KimDYJoeSGYangHSLeeJYKimJGYoonYHSubfoveal choroidal thickness changes in treated idiopathic central serous chorioretinopathy and their association with recurrenceRetina20153591867187425946693
   PubMed Web of Science ®Google Scholar
• BaeSHHeoJWKimCA randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathyAm J Ophthalmol20111525784.e2792.e221742303
   PubMed Web of Science ®Google Scholar
• BaeSHHeoJKimCLow-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trialOphthalmology2014121255856524268858
   PubMed Web of Science ®Google Scholar
• MaierMValetVFeuchtNLohmannCPTherapy options for chronic central serous chorioretinopathy. Photodynamic therapy combined with bevacizumab – a case seriesOphthalmologe20111081110271031 German [with English abstract]22090090
   PubMed Web of Science ®Google Scholar
• ArevaloJFEspinozaJVSingle-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-upGraefes Arch Clin Exp Ophthalmol201124981159116621448811
   PubMed Web of Science ®Google Scholar
• MazarakiKFassnacht-RiederleHBlumRBeckerMMichelsSChange in choroidal thickness after intravitreal aflibercept in pretreated and treatment-naive eyes for neovascular age-related macular degenerationBr J Ophthalmol201599101341134425877895
   PubMed Web of Science ®Google Scholar
• GharbiyaMCrucianiFMariottiCGrandinettiFMarencoMCacaceVChoroidal thickness changes after intravitreal antivascular endothelial growth factor therapy for age-related macular degeneration: ranibizumab versus afliberceptJ Ocul Pharmacol Ther201531635736226133059
   PubMed Web of Science ®Google Scholar
• HolashJDavisSPapadopoulosNVEGF-Trap: a VEGF blocker with potent antitumor effectsProc Natl Acad Sci U S A20029917113931139812177445
   PubMed Web of Science ®Google Scholar
• PitcherJD3rdWitkinAJDeCroosFCHoACA prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: the CONTAIN studyBr J Ophthalmol201599684885225595177
   PubMed Web of Science ®Google Scholar
• MansourAMAshrafMDedhiaCJCharbajiASoukaAARChhablaniJLong-term safety and efficacy of ziv-aflibercept in retinal diseasesBr J Ophthalmol2017101101374137628270485
   PubMed Web of Science ®Google Scholar
• SaitoMIidaTKanoMItagakiKTwo-year results of combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathyGraefes Arch Clin Exp Ophthalmol201325192099211023553286
   PubMed Web of Science ®Google Scholar
• SakuradaYIijimaHTwo-year results of photodynamic therapy with or without intravitreal ranibizumab for polypoidal choroidal vasculopathyJ Ocul Pharmacol Ther201329983283623962035
   PubMed Web of Science ®Google Scholar
• MukaiRKishiSSatoTWatanabeGMatsumotoHProtective effect of intravitreal bevacizumab and sub-Tenon triamcinolone acetonide against occlusion of choriocapillaris induced by photodynamic therapyOphthalmologica2010224526727320185940
   PubMed Web of Science ®Google Scholar
• KangHMKohHJTwo-year outcome after combination therapy for polypoidal choroidal vasculopathy: comparison with photodynamic monotherapy and anti-vascular endothelial growth factor monotherapyOphthalmologica20142312869324135710
   PubMed Web of Science ®Google Scholar
• KimGARimTHLeeSCClinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patientsEye (Lond)2015296732740 quiz 74125952951
   PubMed Web of Science ®Google Scholar
• BalaratnasingamCDhrami-GavaziEMcCannJTGhadialiQFreundKBAflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degenerationClin Ophthalmol201592355237126719668
   PubMed Web of Science ®Google Scholar